Inspira Technologies, a pioneer in life-support medical technology, has announced positive initial results from testing its innovative bio-electronic patch designed to prevent bloodstream infections in critical patients. The ex-vivo porcine skin model testing demonstrated a significant bacterial reduction of 95% within four hours, with continued effectiveness over a 24-hour period.
“We believe that these initial results represent an important milestone in our development of next-generation infection prevention technology,” said Dagi Ben-Noon, CEO of Inspira. “With an estimated 250,000 bloodstream infections related to intravenous lines occurring worldwide each year, we believe this novel approach could potentially offer significant advantages in critical care settings.”
The bio-electronic patch utilizes physical electric stimulation rather than chemical agents to prevent pathogen growth on treated surfaces. This method addresses key challenges associated with traditional IV dressings by:
- Preventing bacterial growth through physical means
- Potentially extending wear time, reducing the frequency of dressing changes
- Being applicable to both skin surface and cannula areas
- Offering real-time monitoring capabilities
Testing followed adjusted standardized protocols, including the AATCC TM100 standard for antimicrobial performance. Results consistently showed bacterial reduction under active patches compared to controls, indicating the technology’s potential effectiveness in a clinical setting.
Building on a Series of Innovations
This announcement adds to Inspira’s recent strides in medical technology advancements. Earlier, the company integrated a new oxygenation indicator into its AI-powered HYLA™ blood sensor technology. The enhancement is designed to enable rapid detection of critical oxygen-related conditions without the need for intermittent blood draws.
“The integration of this new oxygenation indicator into HYLA will enable healthcare providers to monitor and respond to changes in tissue oxygenation in real-time,” noted Ben-Noon. “We continue to advance in our clinical evaluation program and look forward to sharing preliminary clinical results with the public in the near future.”
Advancements in the INSPIRA™ ART100 System
Inspira has also been working on enhancing user support features for its FDA-cleared INSPIRA™ ART100 system. The company introduced advanced features designed to assist medical teams, reduce staff overhead, and improve efficiency in critical care settings.
“Our goal is to develop systems that support medical professionals in their work to treat patients and save lives,” Ben-Noon stated. “These additions reflect our commitment to being pioneers in the life support sector.”
Strategic Deployments and Leadership Changes
Inspira is preparing its INSPIRA™ ART100 systems for deployment at leading U.S. hospitals. The company announced that the systems will be distributed to hospitals on the U.S. east coast, including a cardiothoracic surgery division at a top-ranked New York hospital.
Additionally, Inspira appointed Tal Parnes as the new chairman of the board. Parnes brings over three decades of experience in the medical technology and pharmaceutical industries, enhancing the company’s leadership as it continues to innovate.
Looking Ahead
With the positive initial results of the bio-electronic patch and continuous advancements in their product line, Inspira Technologies is positioning itself at the forefront of infection prevention and critical care technology. The company’s focus on integrating cutting-edge solutions with practical applications aims to address some of the most pressing challenges in healthcare today.
Ben-Noon summarized the company’s outlook: “We continue to push the boundaries of what’s possible in medical technology, always with the goal of improving patient outcomes and supporting healthcare professionals worldwide.”
Subscribe for More Articles Like This
*Disclaimer: Nothing in this report constitutes financial or investment advice, nor does it represent an offer to buy or sell securities. This report is published by Wall Street Wire™. The operators of Wall Street Wire are not registered brokers, dealers, or investment advisers. This report contains paid promotional content related to Inspira Technologies and was produced as part of their paid subscription to Wall Street Wire. Please review the full disclaimers and compensation disclosures here: redditwire.com/terms.